Global Cholera Vaccines Market, By Type (Dukoral, Shanchol, Euvichol), Route of Administration (Oral), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Cholera Vaccines Market Analysis and Size
An estimated 1.3 to 4.0 million cases of cholera are witnessed each year, with 21,000 to 1,43,000 deaths globally. In this regard, cholera vaccines are much in use. Several major market players are producing efficient and cost-effective cholera vaccines, which is estimated to boost the growth of the market. As cholera is a well-known public health threat, the governments are making major investments to provide improved water and sanitation facilities to the least privileged population, which remains largely affected by the disease because of poor sanitation.
Data Bridge Market Research analyses a growth rate in the cholera vaccines market in the forecast period 2023-2030. The expected CAGR of cholera vaccines market is around 9.1% in the mentioned forecast period. The market was valued at USD 95.22 million in 2022, and it would grow upto USD 191.13 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Cholera Vaccines Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Dukoral, Shanchol, Euvichol), Route of Administration (Oral), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Valneva SE. (France), EMERGENT (U.S.), Astellas Pharma Inc. (Japan), Sanofi (France), EUBIOLOGICS CO., LTD (South Korea), Johnson & Johnson Services Inc. (India), Celldex Therapeutics.(U.S.), Merck & Co., Inc. (U.S.), GSK plc (U.K.)
|
|
Market Opportunities
|
|
Market Definition
Cholera is a type of infectious disease caused by ingesting food and water contaminated with the bacterium named as vibrio cholera. The infection has short incubation period from few hours to five days. Cholera can be fatal sometimes. The cholera vaccine inserts a small dose of live cholera bacteria in the body which helps to develop immunity against the disease. It can be given orally, intradermally or intramuscularly in the body.
Cholera Vaccines Market Dynamics
Drivers
- Rising Incidence of Cholera Cases
As per the WHO statistics, an estimated 1.3 to 4.0 million cases of cholera are witnessed every year. The disease impacts any age group starting from children as well as adults and can result in death, if left untreated. Cholera is associated to the decreased availability of clean water and sanitation facilities. In this regard, the WHO Global Task Force on Cholera Control (GTFCC) a program aimed at controlling the spread of cholera by 2030, was launched to decrease the mortality risk related with the disease by 90% in cholera prone areas such as Asia and Africa. This is contributing to the increased demand for cholera vaccines worldwide.
Opportunities
- Rising Demand of Dukoral
Dukoral is projected to hold a major share of the market. Dukoral is the only oral (drinkable) vaccine available in the market, that provides protection against diseases such as cholera and diarrhoea caused by Enterotoxigenic E. coli (ETEC) which is contributes somewhat to increasing the market growth. Additionally, Dukoral can be given to adults and children 2 years of age and older. Besides this, the increasing population in the cholera endemic region as well as the individuals travelling to the said region are also estimated to boost the segment growth in the upcoming years.
- Increasing Awareness About the Disease
The growing concerns associated with cholera outbreaks and the advent of new strains which might be of greater severity are leading to a rise in R&D activities by both government and private bodies. The increasing awareness related to the vaccines and the increased availability of oral vaccines in the region are also projected to boost the market growth in the coming years. The wide adoption of water, sanitation, and hygiene practices has proven to be effective in protecting the population, combined with the use of oral cholera vaccines (OCVs).
Restraints/Challenges
- Longer time required for production of vaccine
The time required to complete a batch of vaccine is pretty long and thus can work as a restrict to the market. The time varies slightly as a function of production scale and varies from 41 h in case of the 1 L scale process to 48.2 h in case of the 30 L scale process. Thus, it restricts the market growth.
- High Cost For Drug Development
The current treatment options for cholera vaccines are limited to antibiotics, and numerous pharmaceutical companies are presently focusing on developing non-antibiotic alternatives. Developing a new class of drugs will offer many growth opportunities for key players, but it will also essentially require major investments in R&D activities of novel therapies. The considerably high investment requirements may act as an obstacle to market growth.
This cholera vaccines market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the cholera vaccines market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Cholera Vaccines Market Scope
The cholera vaccines market is segmented on the basis of type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Dukoral
- Shanchol
- Euvichol
Route of Administration
- Oral
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Cholera Vaccines Market Regional Analysis/Insights
The cholera vaccines market is analyzed and market size insights and trends are provided by type, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the cholera vaccines market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America has been witnessing a positive growth for cholera vaccines market throughout the forecasted period due to the presence of key commodity production, high research and development and healthcare expenditure and trained practitioners.
Asia-Pacific dominates the market due to an increased prevalence of chronic diseases and poor sanitation conditions.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Cholera Vaccines Market Share Analysis
The cholera vaccines market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to cholera vaccines market.
Key players operating in the cholera vaccines market include:
- Valneva SE. (France)
- EMERGENT (U.S.)
- Astellas Pharma Inc.(Japan)
- Sanofi (France)
- EUBIOLOGICS CO., LTD (South Korea)
- Johnson & Johnson Services Inc. (India)
- Celldex Therapeutics. (U.S.)
- Merck & Co., Inc. (U.S.)
- GSK plc (U.K.)
SKU-